News UK biotechs T-Therapeutics and Alethio score big financings Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.
News NICE backs Keytruda/Padcev combo for bladder cancer Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.
News Boehringer forges $7bn alliance with China's SBP Group Boehringer Ingelheim is paying $358m upfront for options on up to six antibody-drug conjugates and T-cell engagers from China's Sino Biopharma.
R&D Why the best CROs challenge the trial plan and keep challeng... Too often, oncology trials fail for reasons that could have been anticipated and addressed.
News Hutchmed, AZ file Orpathys for lung cancer on ESMO data Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.
News Dren Bio pockets $350m for rare blood cancer programme Dren Bio has closed a sizeable private financing round, raising $350m for pivotal trials of a possible first-in-class therapy for rare blood cancers.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.